MedGenome is the leading provider of genomic solutions for populations in South Asia and provides advanced genetic testing and bioinformatics solutions to patients, pharmaceutical companies, and research institutions around the world.
MedGenome is on a mission to improve global health by decoding the genetic information contained in an individual’s genome.
MedGenome was founded in 2013 by Sam Santhosh, alongside with Mahesh Pratapneni. The company is headquartered in Bangalore, Karnataka and Foster City, California.
MedGenome offers end-to-end solutions for next-generation sequencing based assays for a wide range of sample types (such as DNA, RNA, PBMCs, purified CD4 and CD8+ T-cells, splenocytes, TILs, T-cell lines and B-cells).
MedGenome's proprietary cancer immunotherapy solution, OncoPept combines tumor-derived genomic and transcriptomic data to map the molecular features of the tumor and predict personalized cancer immunotherapy combinations with neoantigen vaccines for therapy.
MedGenome has administered more than 300,000 complex genetic tests and served over 200,000 patients. The Company obtains samples from nearly 4,000 hospitals and 10,000 physicians across the globe.
MedGenome is backed by LeapFrog Investments, Sofina, Sequoia Capital, IFC, Novo Holdings, HDFC Ltd., Emerge Ventures, and others. The company raised $50M in a new round on Aug 30, 2022. This brings MedGenome's total funding to $185.5M to date.